Lung Non-Small Cell Carcinoma — Research

Lung Non-Small Cell Carcinoma — Research · CancerIndex

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

pubmedComputed3 windows · counts computed by CancerIndex from PubMed E-utilities; the exact query is stored with each count.

Window	Period	Records (count)	Exact query	Computed	Source
All time	… → 2026-09-11	84,720	`("Carcinoma, Non-Small-Cell Lung"[mh] OR "Lung Carcinoma, Non-Small-Cell"[mh] OR "Nonsmall Cell Lung Cancer"[mh])`	2026-09-11	pubmed
Last 5 years	2021-01-01 → 2026-12-31	26,886	`("Carcinoma, Non-Small-Cell Lung"[mh] OR "Lung Carcinoma, Non-Small-Cell"[mh] OR "Nonsmall Cell Lung Cancer"[mh]) AND (2021/01/01:2026/12/31[dp])`	2026-09-11	pubmed
Last 12 months	2025-09-11 → 2026-09-11	4,343	`("Carcinoma, Non-Small-Cell Lung"[mh] OR "Lung Carcinoma, Non-Small-Cell"[mh] OR "Nonsmall Cell Lung Cancer"[mh]) AND (2025/09/11:2026/09/11[dp])`	2026-09-11	pubmed

Data updated 20 days agoSource updated unknownsource: pubmed E-utilities

Literature

Linked publications (372)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedPublishedShowing 301–325 of 372 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

The Hsp90 inhibitor IPI-504 rapidly lowers EML4-ALK levels and induces tumor regression in ALK-driven NSCLC models.
· Oncogene · 2011 · PMID 21258415 · validated civic_curation pubmed
The ALK/ROS1 Inhibitor PF-06463922 Overcomes Primary Resistance to Crizotinib in ALK-Driven Neuroblastoma.
· Cancer Discov · 2016 · PMID 26554404 · validated civic_curation pubmed
The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer.
· Cancer Discov · 2014 · PMID 24675041 · validated civic_curation pubmed
MET tyrosine kinase inhibitor crizotinib (PF-02341066) shows differential antitumor effects in non-small cell lung cancer according to MET alterations.